Skip to Content

Reprogramming Stem Cells with Drugs

New research brings stem cells one step closer to clinical use.

Last year, scientists from Japan and the United States revolutionized stem-cell research by demonstrating that they could revert adult cells to an embryonic state just by expressing a few genes. The findings provide a source of cells that, like embryonic stem cells, can theoretically be transformed into any type of cell, and thus could be useful in cell replacement therapies, as for Parkinson’s or diabetes. The new cells come without the technical and ethical hurdles of embryonic stem cells and could therefore drastically speed research in this area.

One drawback to the research, however, is that scientists had to genetically alter the cells. While that’s fine for research purposes, it limits the cells’ potential use in humans. Now scientists report that they can use drugs rather than genes to revert adult skin cells to their embryonic state.

According to a report in the Telegraph,

“This shows that we can make cell reprogramming technology much more practical than it has been,” says Dr. [Sheng] Ding, an associate professor at Scripps Research and a chemist who studies stem cell biology. “These advances will bring us closer to the day when we can use these powerful cells to make any kind of human tissue that we need to help patients.”

[While previous research] used four genes, at least two linked with cancer, to turn back the clock so they became more embryo like, Dr. Ding uses just two genes, along with drugs, reducing the need for viruses and doing away with the cancer gene.

Dr. Ding believes that, someday, chemical cocktails might be used instead of viruses to reprogram cells for cell-based therapy. One cocktail of small molecules would be used to revert specialized adult cells back to an earlier developmental stage, and then a second cocktail would differentiate the cell into the type needed to replace diseased cells in any organ or tissue.

“This study is a proof of principle that this kind of approach is possible,” he says.

While opponents of embryonic stem-cell research say that advances in reprogramming mean that the research should be halted altogether, most scientists working in the field say that both approaches should continue because it’s still not clear how closely reprogrammed cells mimic embryonic stem cells.

Keep Reading

Most Popular

AGI is just chatter for now concept
AGI is just chatter for now concept

The hype around DeepMind’s new AI model misses what’s actually cool about it

Some worry that the chatter about these tools is doing the whole field a disservice.

Hoan Ton-That, CEO of Clearview AI
Hoan Ton-That, CEO of Clearview AI

The walls are closing in on Clearview AI

The controversial face recognition company was just fined $10 million for scraping UK faces from the web. That might not be the end of it.

Europe's AI Act concept
Europe's AI Act concept

A quick guide to the most important AI law you’ve never heard of

The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.